MedTrace Logo

Engineering Immune Organoids to Study Pediatric Cancer

NCT05890781 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2026-02-09

No results posted yet for this study

Summary

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Conditions

Interventions

PROCEDURE

Spinal cerebrospinal fluid (SCF)

Spinal cerebrospinal fluid (SCF) whenever possible

PROCEDURE

Skin biopsy

Skin biopsy

PROCEDURE

Fresh tumor sample

Fresh tumor sample

BIOLOGICAL

Blood sample

Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached

PROCEDURE

Healthy tissue from the tumor

Healthy tissue from the tumor site whenever possible

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-12
Primary Completion
2028-05-31
Completion
2028-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05890781 on ClinicalTrials.gov